EUVIMEDEUVIMED entdecken
Crossref

SPHK1 / S1P / S1PR pathway promotes the progression of peritoneal fibrosis by mesothelial‐mesenchymal transition

Tingting Zhao iD, Tao Ding iD, Zhengyu Sun iD, Xin Shao iD, Shuangxi Li iD, Hongtao Lu iD, Ji-Hang Yuan iD, Zhiyong Guo iD

The FASEB Journal · 31.01.2024 · 38 (2)

DOI: 10.1096/fj.202301323r ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, online erschienen am 16.01.2024. Verfasst von Tingting Zhao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, First Affiliated Hospital of Naval Medical University, Shanghai Changhai Hospital, Shanghai, China. Hauptthemen laut MEDLINE: Peritoneal Fibrosis, Lysophospholipids, Phosphotransferases (Alcohol Group Acceptor). Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: MOST | National Natural Science Foundation of China (NSFC), Climbing Program of Changhai Hospital, Shanghai Sailing Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Long‐term exposure to non‐physiologically compatible dialysate inevitably leads to peritoneal fibrosis (PF) in patients undergoing peritoneal dialysis (PD), and there is no effective prevention or treatment for PF. Sphingosine‐1‐phosphate (S1P) is a bioactive sphingolipid produced after catalysis by sphingosine kinase (SPHK) 1/2 and activates signals through the S1P receptor (S1PR) via autocrine or paracrine. However, the role of SPHK1/S1P/S1PR signaling has never been elucidated in PF. In our research, we investigated S1P levels in peritoneal effluents and demonstrated the role of SPHK1/S1P/S1PR pathway in peritoneal fibrosis. It was found that S1P levels in peritoneal effluents were positively correlated with D/P Cr ( r = 0.724, p < .001) and negatively correlated with 4 h ultrafiltration volume ( r = −0.457, p < .001). S1PR1 and S1PR3 on peritoneal cells were increased after high glucose exposure in vivo and in vitro. Fingolimod was applied to suppress S1P/S1PR pathway. Fingolimod restored mouse peritoneal function by reducing interstitial hyperplasia, maintaining ultrafiltration volume, reducing peritoneal transport solute rate, and mitigating the protein expression changes of fibronectin, vimentin, α‐SMA, and E‐cadherin induced by PD and S1P. Fingolimod preserved the morphology of the human peritoneal mesothelial cells, MeT‐5A, and moderated the mesothelial‐mesenchymal transition (MMT) process. We further delineated that SPHK1 was elevated in peritoneal cells after high glucose exposure and suppression of SPHK1 in MeT‐5A cells reduced S1P release. Overexpression of SPHK1 in MeT‐5A cells increased S1P levels in the supernatant and fostered the MMT process. PF‐543 treatment, targeting SPHK1, alleviated deterioration of mouse peritoneal function. In conclusion, S1P levels in peritoneal effluent were correlated with the deterioration of peritoneal function. SPHK1/S1P/S1PR pathway played an important role in PF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peritoneal FibrosisLysophospholipidsPhosphotransferases (Alcohol Group Acceptor)AnimalsMiceHumansFingolimod HydrochlorideGlucoseSphingosineSphingosine Kinase

Stichwörter der Autor:innen

FingolimodSphingosine-1-phosphateperitoneal fibrosissphingosine kinase

Substanzen

Fingolimod HydrochlorideGlucoseLysophospholipidsSphingosinePhosphotransferases (Alcohol Group Acceptor)Sphingosine Kinasesphingosine 1-phosphate

Autor:innen und Institutionen

  • Department of Nephrology, First Affiliated Hospital of Naval Medical University, Shanghai Changhai Hospital, Shanghai, China.
  • Department of Nephrology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
  • Department of Endocrinology, Xizang Military General Hospital, Lhasa City, China.
  • Department of Cardiovascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Department of Nutrition, Naval Medical University, Shanghai, China.
  • Department of Medical Genetics, Naval Medical University, Shanghai, China.

ORCID-Profile: Tingting Zhao, Tao Ding, Zhengyu Sun, Xin Shao, Shuangxi Li, Hongtao Lu, Ji-Hang Yuan, Zhiyong Guo

Förderung

  • MOST | National Natural Science Foundation of China (NSFC)
  • Climbing Program of Changhai Hospital
  • Shanghai Sailing Program
  • National Natural Science Foundation of China

Zitieren

APA

Zhao, T., Ding, T., Sun, Z., Shao, X., Li, S., Lu, H., Yuan, J. H., & Guo, Z. (2024). SPHK1 / S1P / S1PR pathway promotes the progression of peritoneal fibrosis by mesothelial‐mesenchymal transition. The FASEB Journal, 38(2). https://doi.org/10.1096/fj.202301323r

Vancouver

Zhao T, Ding T, Sun Z, Shao X, Li S, Lu H, et al. SPHK1 / S1P / S1PR pathway promotes the progression of peritoneal fibrosis by mesothelial‐mesenchymal transition. The FASEB Journal. 2024;38(2). doi:10.1096/fj.202301323r

BibTeX
@article{Zhao2024,
  author = {Zhao, Tingting and Ding, Tao and Sun, Zhengyu and Shao, Xin and Li, Shuangxi and Lu, Hongtao and Yuan, Ji-Hang and Guo, Zhiyong},
  title = {SPHK1 / S1P / S1PR pathway promotes the progression of peritoneal fibrosis by mesothelial‐mesenchymal transition},
  journal = {The FASEB Journal},
  year = {2024},
  volume = {38},
  number = {2},
  doi = {10.1096/fj.202301323r}
}
Kostenlos starten →